

Global Corporate Headquarters  
7 Argent Place, Ringwood  
Victoria 3134, Australia  
Tel: +61 (0) 3 9837 4200  
[www.trajanscimed.com](http://www.trajanscimed.com)

Trajan Group Holdings Limited  
ACN 152 617 706

**ASX RELEASE****Results of 2025 Annual General Meeting**

**28 October 2025** – Global analytical science and device company Trajan Group Holdings Limited (**ASX: TRJ**) (**Trajan or the Company**) advises that in accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions put to shareholders of Trajan at its 2025 Annual General Meeting held earlier today.

**Authorised for ASX release by the Company Secretary of Trajan Group Holdings Limited.**

**END**

**Contact:****Investors**

Marie Krstic

[investorrelations@trajanscimed.com](mailto:investorrelations@trajanscimed.com)

**Media**

Ana Luiza Graça Harrop

[media@trajanscimed.com](mailto:media@trajanscimed.com)

**About Trajan**

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	40,342,169 99.28%	290,494 0.71%	4,618 0.01%	209,146	40,938,787 99.30%	290,494 0.70%	209,146	Carried
2 Re-election of Dr Rohit Khanna as a Director	Ordinary	117,320,273 99.52%	569,720 0.48%	4,618 0.00%	242,529	119,663,957 99.53%	567,426 0.47%	448,411	Carried
3 Grant of Options to Director - Mr John Eales	Ordinary	116,909,624 99.40%	704,915 0.60%	4,987 0.00%	517,614	117,713,712 99.40%	704,915 0.60%	2,261,167	Carried
4 Grant of Options to Director - Dr Rohit Khanna	Ordinary	117,174,739 99.40%	710,880 0.60%	4,618 0.00%	246,903	119,516,129 99.41%	710,880 0.59%	452,785	Carried
5 Grant of Options to Director - Ms Tiffany Lewin	Ordinary	117,174,739 99.36%	750,415 0.64%	4,618 0.00%	207,368	119,019,507 99.37%	750,415 0.63%	909,872	Carried
6 Grant of Options to Director - Ms Sara Watts	Ordinary	100,929,937 85.69%	16,853,960 14.31%	4,618 0.00%	348,625	102,885,209 85.92%	16,853,960 14.08%	940,625	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.